Abstract. tTF-NGR consists of the extracellular domain of the (truncated) tissue factor (tTF), a central molecule for coagulation in vivo, and the peptide GNGRAHA (NGR), a ligand of the surface protein aminopeptidase N (CD13). After deamidation of the NGR-peptide moiety, the fusion protein is also a ligand for integrin · v ß 3 (CD51/CD61). Both surface proteins are upregulated on endothelial cells of tumor vessels. tTF-NGR showed binding to specific binding sites on endothelial cells in vitro as shown by flow cytometry. Subcutaneous injection of tTF-NGR into athymic mice bearing human HT1080 fibrosarcoma tumors induced tumor growth retardation and delay. Contrast enhanced ultrasound detected a decrease in tumor blood flow in vivo after application of tTF-NGR. Histological analysis of the tumors revealed vascular disruption due to blood pooling and thrombotic occlusion of tumor vessels. Furthermore, a lack of resistance was shown by re-exposure of tumor-bearing mice to tTF-NGR after regrowth following a first cycle of treatment. However, after subcutaneous (s.c.) push injection with therapeutic doses (1-5 mg/kg bw) side effects have been observed, such as skin bleeding and reduced performance. Since lethality started within the therapeutic dose range (LD 10 approximately 2 mg/kg bw) no safe therapeutic window could be found. Limiting toxicity was represented by thrombo-embolic events in major organ systems as demonstrated by histology. Thus, subcutaneous injection of tTF-NGR represents an active, but toxic application procedure and compares unfavourably to intravenous infusion.
Introduction
The formation of new blood vessels is essential for spread and metastasis of solid tumors (1) and is also observed in some hematological malignancies (2) . This process assures supply of oxygen and nutrients as well as removal of metabolic waste products (3) . Angiogenesis and neovascular endothelial cells have become promising targets for antitumor therapy, as the inhibition of blood supply subsequently should lead to reduction of tumor growth (3, 4) .
To date, mainly two strategies affecting tumor blood supply have been developed. The first one inhibits angiogenesis by interfering with the process of formation of new blood vessels. Representative drugs of this group, such as the monoclonal antibody against Vascular Endothelial Growth Factor (VEGF) bevacizumab, are already clinically established (5) . An alternative approach is to destroy already existing tumor blood vessels by so-called vascular disrupting agents (VDA), such as combretastatins (3) . Damaging tumor blood vessels will disrupt both upstream and downstream function with subsequent cell death. In this regard, tumor vasculature is considered as the 'Achilles' heel' of solid tumors. Even a change of shape or function of endothelial cells may be adequate to destabilize the vascular system in tumors.
Direct contact to blood flow makes tumor endothelial cells easy to reach, and Denekamp et al were the first to propose these endothelial cells as a target for antitumor therapy (6) . Specific tumor vessel markers such as the vascular endothelial growth factor-receptor 2 (7), endosialin (8) , the matrixmetalloproteinases (9) , several integrins such as · v ß 3 (10) , INTERNATIONAL JOURNAL OF ONCOLOGY 37: 1389 -1397 , 2010 Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: Activity and toxicity profile · v ß 5 (11) , · 1 ß 1 and · 2 ß 1 (12) , and NG2 proteoglycan (13) and others are promising targets for specific ligands (14) (15) (16) (17) (18) coupled with cytotoxic and proapoptotic substances and targeting these effector molecules to tumor endothelial cells. This design of molecules appropriate for vascular targeting is to be conceptually separated from the use of small molecule VDA exploiting specific characteristics of the tumor vasculature and disrupting tumor vessels. Several agents of this latter group such as combretastatins and flavonoids are tested in clinical trials (19) .
Here we report on data targeting the tissue factor (TF), a central initiator of the extrinsic coagulation pathway in vivo, to tumor vessels which results in tumor vessel infarction and cell death. The lack of coagulation inducing activity of a soluble form of TF missing its transmembrane domain (truncated TF: tTF) (20) can partly be recovered by relocalizing tTF into the proximity of a phospholipid membrane (21) . Accordingly, targeting tTF via peptides and antibodies to specific tumor vessel markers including the MHC complex (21) , the ED-B domain of fibronectin (22) , the prostate specific antigen (23), the vascular cell adhesion molecule (VCAM-1) (24) , and integrins such as · v ß 3 (25) has lead to rapid induction of thrombosis in tumor vessels.
Recent studies revealed that small peptides containing the NGR motif (asparagine-glycine-arginine) bind to aminopeptidase N (APN; CD13) (26) , a surface molecule with upregulated expression on endothelial cells in tumors and tissues that undergo angiogenesis. NGR binds differentially to CD13 in tumor vasculature, but not to CD13 in normal kidney and myeloid cells (27) . In addition, NGR undergoes a rapid nonenzymatic asparagine deamidation to isoaspartate-glycinearginine (isoDGR) generating a further ligand for · v ß 3 (28, 29) . We have constructed fusion proteins consisting of NGRpeptide sequences coupled to the C-terminal end of tTF (30, 31) . Several of these fusion proteins including tTF-NGR, retain their thrombogenic activity in vitro, bind to their respective targets on endothelial cells, and upon intravenous (i.v.) infusion induce thrombosis in blood vessels in several solid tumors in mice with subsequent tumor growth retardation and regression (30, 31) . I.v. infusion of tTF-NGR in cancer patients at dose levels without side effects was shown to reduce tumor blood flow in situ (30) . In this study, we have analysed antitumor activity and toxicity profile of s.c. injection of tTF-NGR in human tumor xenograft models, s.c. injection of tTF-NGR represents an active but toxic way of application and compares unfavourably to the i.v. infusion of the compound.
Materials and methods
Cloning, expression, and purification of proteins. The cDNA coding for tTF containing amino acids 1-218 and tTF-GNGRAHA, in which the heptapeptide is linked to the Cterminus of tTF (tTF-NGR), was amplified by polymerase chain reaction (PCR) using the primers 5'-CATGCCATGGG ATCAGGCACTACAAATACTGTGGCAGCATATAAT-3' (5'-Primer), 5'-CGGGATCCTATTATGCATGTGCTCTTC CGTTACCTCTGAATTCCCC-3' (3'-Primer) for tTF-NGR. With the DNA-Ligation kit (Novagen, Schwalbach am Taunus, Germany) the cDNA was cloned into the expression vector pET30a(+) (Novagen) using the BamHI and NcoI sites of the vector. The generated tTF constructs possess an Nterminal histidine tag for the subsequent purification of the proteins by using immobilized metal-chelate affinity chromatography.
The vectors were introduced into competent E. coli cells (BL21 DE3) according to the manufacturer's protocol (Novagen). After stimulating with IPTG (Novagen), the cells were harvested and 5-7 ml lysis buffer (10 mM Tris-HCl, pH 7.5; 150 mM NaCl; 1 mM MgCl 2 ; 10 μg/ml aprotinin; 2 mg/ml lysozyme) per gram wet weight and 20 μl benzonase (Novagen) were added to the pellet. Then the cells were incubated for 90 min at room temperature (RT) and centrifuged at 12,000 x g for 20 min at 4˚C. The pellet was resuspended and homogenized by sonicating in washing buffer (10 mM Tris/HCl, pH 7.5; 1 mM EDTA (ethylene-diaminetetraacetic acid), 3% Triton X-100). To solubilize the inclusion bodies, 2-4 ml guanidinium buffer [6 M GuCl, 0.5 M NaCl, 20 mM Tris/HCl, pH 7.5, and 1 mM dithiothreitol (DTT)] per gram wet weight was added. After incubation overnight at RT, the suspension was centrifuged at 10,000 x g for 15 min at 4˚C. The supernatant was filtered through a 0.22-μm filter and stored at -25˚C. To upscale the manufacturing procedure a multistep HPLC-based purification process has been established (HPLC unit: ÄKTA purifier 100 system, GE Healthcare, Uppsala, Sweden). The first capture step consists of an immobilized metal-affinity chromatography (IMAC) in which the immunogenic nickel is replaced by copper (IMAC Sepharose 6 FF, GE Healthcare). The histidine-tagged (Nterminus) tTF-NGR fusion protein binds to the immobilized copper ions so that the complete refolding (urea gradient from 6 to 0 M) and washing processes are performed on the column, from which the tTF-NGR protein is eluted by applying 300 mM imidazole. During the subsequent gel filtration the IMAC eluate is conditioned by a buffer exchanging step using Sephadex G-25 (GE Healthcare) in order to prepare for the following intermediate purification step. This anionexchange chromatography step (AIEX; Q Sepharose HP, GE Healthcare) allows further separation of the eluted proteins according to differences in their net charges. Moreover, it removes most of the remaining impurities such as other proteins, nucleic acids and endotoxines. The concluding polishing step again comprises a gel filtration using Sephadex G25 in order to remove any remaining trace impurities and to exchange the buffer to PBS. The final protein solutions are stored at -80˚C.
The tTF-NGR protein was analyzed under denaturing conditions on SDS-PAGE and Western blotting using mouse monoclonal anti-human tissue factor antibody (American Diagnostica, Pfungstadt, Germany; dilution 1:1000). Besides, every charge was analyzed by the Factor-X coagulation assay. Here, the ability of the tTF-NGR protein to enhance the specific proteolytic activation of FX by FVIIa was evaluated by Michaelis-Menten analyses (32) . Analyses of the bacterial endotoxin content of the tTF fusion protein charges have routinely been accomplished by a certified external laboratory (Charles River Laboratories, L'Arbresle, France). The used kinetic chromogenic LAL (Limulus amebocyte lysate) assay was performed in compliance with the European Pharmacopoeia (sensitivity: 0.005 IU/ml). The determined values were always below an endotoxin level of 10 IU/mg protein (1.4-7.1 IU/mg protein). tTF-NGR solutions were micro-filtrated with 22-μm filters before use in the in vivo experiments.
Cell culture. Human umbilical vein endothelial cells (HUVECs)
were from BD Biosciences. The HT1080 fibrosarcoma cell line (30) was cultured in Dulbecco's medium supplemented with 10% fetal calf serum (FCS, Gibco-BRL, Eggenstein, Germany).
Binding studies using flow cytometry. HUVECs were used at low passage numbers and grown in serum-supplemented medium. We applied flow cytometry using monoclonal antibodies (AB) against CD13 (BD Biosciences, Heidelberg; cat. no. 347837, PE-linked), · v ß 3 (CD51/CD61; BD Pharmingen, Heidelberg, cat. no. 550037, PE-linked) to verify presence of these molecules on HUVECs (details not shown) (30) . For binding analysis, cells were blocked using human immunoglobulin (Ig), washed and incubated with His-tag-tTF-NGR for 20 min at RT at different concentrations as specified. Subsequently, cells were washed twice (PBS/ 1% bovine serum albumin (BSA)/0.1% NaN 3 ) and incubated with either PE-linked anti-CD13 antibody, PE-linked anti-CD51/CD61 antibody or isotype control antibody (BD Biosciences) as specified for 30 min at 37˚C. After 3 further washing steps, cells were directly measured using a FACSCalibur™ flow cytometer (Becton-Dickinson, San Jose, USA). To show that cells remaining without anti-CD13 or anti-CD51/CD61 binding in these assays had surface-bound His-tag-tTF-NGR present, cells were (after washing) incubated with mouse anti-His-tag (Novagen, Madison, WI, USA, cat. no. 70796) antibody, washed twice, incubated with fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse secondary Ig (BD Biosciences; indirect immunofluorescence), washed x3, and measured.
Effect of tTF-NGR on apoptosis of endothelial cells in vitro.
To test for a putative cell death-inducing potential of the tTF-NGR protein after binding to endothelial cells, cytoplasmic histone-associated DNA fragments were determined by the use of the Cell Death Detection ELISA Plus kit from Roche (Mannheim, Germany) according to the manufacturer's instruction. HUVECs (2.5x10 4 cells/ml) were incubated with different protein concentrations for 18 h. The apoptosis inducer camptothecin was used as positive control.
Effect of tTF-NGR on proliferation of endothelial cells in vitro.
To quantify a putative effect on endothelial cell proliferation of tTF-NGR, the incorporation of the thymidine analogue bromodeoxyuridine (BrdU) during the DNA synthesis was measured colorimetrically by the use of the Cell Proliferation ELISA from Roche (Mannheim, Germany) according to the manufacturer's instruction. HUVECs (1x10 5 cells/ml) were incubated with different protein concentrations for 32 h. The subsequent BrdU incorporation was performed for additional 16 h.
Animals. All procedures on animals were performed in agreement with German regulations (Tierversuchsgesetz § 8 Abs. 2) and specifically approved in form of a project license.
Five to seven week-old CD-1 nude mice were purchased from Charles River Laboratories (Sulzfeld, Germany) and acclimated to our animal-experiment facility for at least 1 week before any examination. Mice were maintained on a 12:12-h light:dark cycle in a low-stress enviroment (22˚C, 50% humidity, low noise) and given food and water ad libitum.
Tumor mouse models. The tumor cells for the experiments were grown as attached monolayer cultures, dissociated in trypsin, centrifuged, washed and resuspended in PBS. For evaluation of the antitumor effect, mice were injected s.c. with the HT1080 cells in one rear flank with 4x10 6 cells/mouse in 100 μl. To estimate the volume of the tumor, its exposed surface was measured in two perpendicular directions and the volume was calculated as (length x width 2 x /6). Tumor growth was allowed to a volume of approximately 500-2000 mm 3 . Different tumor volumes were chosen as starting points for randomization and treatment to study possible tumor growth retarding effects of early and tumor shrinkage of late treatment onset. The mice were randomly assigned to different experimental groups. Saline or experimental drugs were injected s.c. distant from the tumors using various schedules and doses. To study development of resistance, mice with regrowing tumors after a first cycle of treatment were re-exposed to s.c. treatment with tTF-NGR after an observation period without therapy; control mice with tumors at similar size were treated for the first time in parallel.
Histology. Histological analyses were performed on paraformaldehyde fixed (4%) and paraffin-embedded tissues as described earlier (2) . Briefly, tissues embedded in paraffin were cut to 4-μm sections and transferred onto glass slides. For identification of thrombosis and organic pathologies, H&E stained sections were examined using conventional light microscopy in a blinded fashion.
Blood tests. Blood for analysis of coagulation parameters was received by transthoracic puncturing of hearts with animals under anaesthetic. Subsequent determination of PTT (partial thromboplastin time), TT (thrombin time) and Quick-value was accomplished by standard procedures.
Contrast enhanced ultrasound. Contrast enhanced ultrasound (CEUS) was performed using an ultrasound machine dedicated for small animal CEUS (Vevo 2100, Visualsonics, Toronto, Canada) equipped with an 18-MHz transducer operating in a contrast specific imaging mode (powermodulation). A commercially available ultrasound contrast agent was constantly injected via a 27G-tail vein catheter using a rotating infusion pump at 20 μl/min (33) . A fixed crosssectional view of the tumor was obtained. The adjacent kidney served as control tissue. Regions of interest were placed either covering the tumor or the kidney during the experiment. Imaging was gated by ECG and respiration to ensure comparable conditions. Steady state of the contrast signal was achieved after 2 min and signal intensity in the control organ was constant during the experiment. Forty-five micrograms tTF-NGR was push-injected s.c. Start of injection marked (t 0) and measurements of linearized signal intensities given in acoustic units (AU) were plotted versus time as previously described (34).
Statistics.
Statistical significance of differences was tested by the Mann-Whitney rank sum test for independent groups. Two-sided P<0.05 were considered significant.
Results
Binding studies with flow cytometry. To study specific binding of tTF-NGR (and deamidation products) with flow cytometry we first characterized HUVECs as carrying relevant (CD13, · v ß 3 ) binding sites (details not shown) (30) . Next, we preincubated HUVECs with increasing concentrations of tTF-NGR (0.3-300 μg/ml His-tag-tTF-NGR) and subsequently measured binding of a constant concentration (5 μg/ml) of either anti-CD13-or anti-CD51/CD61-antibody. As can be seen in Fig. 1A and B (LL) increasing concentrations of tTF-NGR could compete with binding of both antibodies to HUVECs. To further test for presence of tTF-NGR on the cells without anti-CD13-and anti-CD51/CD61-antibody binding we performed subsequent indirect immunofluorescence studies detecting His-tagged tTF-NGR (Fig. 1C and D) . These studies indicate specific binding of tTF-NGR and deamidation products to both known binding sites CD13 and 
Effect of s.c. tTF-NGR injections on growth of HT1080 xenotransplants.
The antitumor activity of tTF-NGR was determined in CD-1 nude mice bearing HT1080 tumors. Drugs and controls were push-injected s.c. five times at intervals of 24 h. Injections of 3, 5 or 7 mg tTF-NGR/kg body weight (bw) induced tumor shrinkage and subsequent growth delay for a longer period of time when compared with saline controls. However, after termination of treatment a regrowth could be observed within some days. S.c. injection of 1 mg/kg bw seemed to have no major influence on tumor growth when compared with saline controls. Representative results are presented in Fig. 2A . Subsequently, we reduced treatment to two subcutaneous push-injections at intervals of 24 h. This regimen also induced a delay of HT1080 tumor growth (Fig. 2B) .
Next, we studied characteristics of tumor growth under prolonged therapy with tTF-NGR. Mice obtained 5 injections in daily intervals and were then randomized to receive 2 further injections with tTF-NGR versus no further treatment. As shown in Fig. 2C , this prolonged application of tTF-NGR could not inhibit tumor regrowth as compared to no further application. In these experiments the activity of tTF-NGR at 3 mg/kg s.c. was comparable to 1 mg/kg i.v. indicating a comparably lower antitumor activity achieved by the s.c. route of application.
In the majority of cases, tumors treated with tTF-NGR showed blue and brown coloration and necrotic areas (Fig. 2D) . In case of overt ulcerations of the tumor animals were sacrificed and censored. Histology revealed blood pooling, vascular disruption and thrombosis in tumor vessels (Fig. 2E) .
Development of resistance.
To study development of resistance, mice with regrowing tumors after the first cycle of therapy were re-exposed to s.c. treatment with tTF-NGR after an observation period of >2 weeks without tTF-NGR therapy, while control mice with tumors at similar size were treated for the first time in parallel. A lack of resistance development upon re-exposure to tTF-NGR could be shown (Fig. 3A) , as HT1080 tumor shrinkage was similar when comparing the effects of 1st versus 2nd treatment cycles.
However, the HT1080 xenograft model revealed some variability of tumor growth and treatment effects: besides experiments, in which we observed therapeutic effects of tTF-NGR, there were few experiments, in which repeated s.c. injections of 2-5 mg/kg bw tTF-NGR induced neither shrinkage nor delay of tumor growth (details not shown). In addition, s.c. injections of 3 mg/kg bw every second day instead of daily injections influenced tumor growth only to a lesser extent (data not shown).
Contrast enhanced ultrasound.
To study the mode of action of the in vivo tTF-NGR activity, CEUS imaging was started immediately after injecting 45 μg tTF-NGR s.c. Shortly after tTF-NGR injection tissue perfusion decreases firstly in the center and consecutively also in the periphery of the tumor. After 15-20 min CEUS depicts a considerable reduction of perfusion signals (Fig. 3B) . The measurements of linearized signal intensities given as AU plotted versus time of observation revealed the decrease of tumor blood flow compared to the blood flow of the control organ kidney (Fig. 3C) .
Toxicity of s.c. tTF-NGR.
Acute tolerability of 1-3 mg/kg bw s.c. was good. Upon s.c. injection of 5 mg/kg bw, mice suffered from visible weakness and exhaustion. Cutaneous hematomas occurred around the injection site within 24 h after treatment (Fig. 4A) . Infrequently, especially after administration of higher doses (>3 mg/kg bw), also distant cutaneous hematomas, e.g. in the face have been observed. Hematomas regressed mostly within one week after termination of treatment. Furthermore, in some mice sudden deaths occurred within 24 h after the first injection of tTF-NGR with preceding clinical signs of dyspnea. During all experiments with s.c. application of tTF-NGR or saline we evaluated the cumulative incidence of sudden deaths according to dose groups (1, 3, 5, 7 mg/kg bw). Cumulative data show an increasing number of deaths within a period until 24 h after termination of treatment with using higher doses of tTF-NGR. Lethal dose for 10% of the animals (LD 10 ) was found at approximately 2 mg/kg (Fig. 4F ). Mice treated with toxic doses of tTF-NGR (7 mg/kg bw s.c.) and those dying upon treatment were subjected to histopathological examination of all major organ systems. Histopathology revealed peripheral pulmonary embolism (Fig. 4B) , necrosis zones in kidneys and liver ( Fig. 4C and D) and parietal thrombus in hearts (Fig. 4E) . All other organs seemed to be unaffected. To further study possible reasons for cutaneous and organ bleeding with parallel pulmonary embolism, we subjected mice to blood coagulation tests upon receiving high doses of tTF-NGR (7 mg/kg bw i.v.). Preliminary results showed parameters compatible with disseminated intravascular coagulation (DIC), as there was elongation of PTT, TT and drop of Quick-value (details not shown).
Analysis of a direct impact of tTF-NGR on vascular endothelial cells.
Thrombotic occlusion of tumor blood vessels with the subsequent reduction of tumor blood flow and tumor necrosis has been shown as the main mode of action of the tTF-NGR therapy (25,30,31) . In order to exclude a direct effect of tTF-NGR on cell death (apoptosis) and on proliferation of vascular endothelial cells, ELISA-based assays have been performed (Fig. 5) . Neither the viability (Fig. 5A ) nor the ability of endothelial cells to proliferate (Fig. 5B) were influenced by tTF-NGR, even at concentrations several-fold higher than those reached in vivo within the therapy experiments (data not shown). We have also assayed tTF-NGR concentrations lower than shown in Fig. 5 with no effects on cell death or proliferation.
Discussion
There have been a few reports on using antibody-coupled tTF for targeting markers of angiogenesis in tumor vessels inducing thrombosis with subsequent growth reduction and tumor shrinkage (21, 22, 24) . Important limitations of using antibodies as targeting moieties for tTF might be their nonspecific accumulation and uptake in the reticuloendothelial system and the immunogenicity of the resulting antibodyeffector molecule complex. Thus, using antibodies fused to tTF could cause dose-limiting procoagulant activities in liver, spleen and bone marrow, as well as neutralizing antibodies. Furthermore, the bigger size of antibodies might cause sterical hindrance and reduced procoagulant activity of tTF. To avoid described limitations, we expressed a fusion protein consisting of a small peptide (GNGRAHA) coupled to the C-terminus of tTF. . In vitro analysis of tTF-NGR effects on endothelial cell death (A) and proliferation (B), respectively. Human umbilical vein endothelial cells (HUVECs) have been incubated with increasing concentrations of the tTF-NGR protein (0.1-100 μg/ml). To test for cell death-inducing potential, the amount of histone-associated DNA fragments after a 16 h-incubation period has been determined in tTF-NGR-incubated HUVECs in comparison to cells incubated in ascending concentrations (0.01-1 μg/ml) of the apoptosis inducer camptothecin (CT). While CT concentrations greater than 0.05 μg/ml clearly induce cell death, no significant apoptotic effect was detectable after tTF-NGR incubation (A). In a colorimetric immunoassay determining the incorporation of BrdU during DNA synthesis of proliferating cells, increasing tTF-NGR concentrations had no effect on proliferation of HUVECs compared to control cells (B). Data of 2-3 independent assays are presented as means ± SE.
The NGR-motif was discovered by in vivo screening of phage libraries (11) , while tTF is part of the tTF:VIIa complex (35), a potent initiator of coagulation. Via aminopeptidase N (CD13), to which small peptides containing the NGR motif can bind, the tTF-NGR fusion protein adopts an orientation perpendicular to the phospholipid membrane of the endothelial cell providing a basis for coagulation. By connecting the peptide to the C-terminus of tTF, sterical hindrance of the interaction of tTF, FVII and FX should be eliminated (35) . In addition, peptides do not bind to the reticuloendothelial system, are chemically stable and easy to derivatize (36) . CD13 is upregulated within tumors (37) and in response to hypoxia and angiogenic growth factors. In addition, the inhibition of the CD13 pathway abrogates endothelial cell migration, invasion and morphogenesis of endothelial cells (38, 39) . Interestingly, there have been reports on differential binding of NGR-drug conjugates, as they bind to CD13 on tumor endothelial cells but not to CD13 expressed on hematopoietic cells and epithelial cells in proximal tubules in the normal kidney (27) . This can be explained by recognition of CD13 isoforms expressed within tumor-associated vessels but not on normal tissues. In addition, higher phosphatidylserine expression within the tumor vasculature might provide additional selectivity for pro-coagulant activities induced by tTF-NGR (27) . A further hypothetical advantage of tTF-NGR is that deamidation of the NGR-peptide may generate iso-DGR, an · v ß 3 ligand which is also upregulated on tumor endothelial cells (28) . Therefore, the described mechanism may allow for targeting of two tumor-specific binding sites by one ligand and might amplify procoagulant activity of tTF-NGR. In the results presented here moreover, we could exclude a dominant direct effect of our tTF-NGR construct on viability or proliferation of endothelial cells as a mechanism underlying the in vivo therapeutic effects. Coagulation inducing activity of i.v. application of tTF-NGR in tumor vasculature with subsequent tumor infarction and growth delay could be shown in several tumor mouse models (30, 31) . The first inman experiences with very low doses of tTF-NGR (1-4 mg/m 2 by i.v. infusion) showed inhibition of tumor perfusion without any side effects (30) .
Whenever working with E. coli derived material, endotoxin/ LPS contamination might complicate interpretation of the results. Philipp et al (40) used minimal 10 ng total dose LPS (1 IU is equivalent to ~0.1 ng), which was able to induce coagulation on tumor endothelium if co-administered with soluble tissue factor. Here, we used tTF-NGR charges that contained approximately 7.5 pg LPS (refering to 1 mg tTF protein/kg bw of a 30-g mouse) up to approximately 50 pg LPS (refering to 7 mg tTF protein/kg bw of a 30-g mouse) per injection, which is 200-1300 times less compared to the administered LPS doses of Philipp et al, excluding endotoxin effects. Furthermore, in previous series of experiments we used non-targeted tTF, produced in the same E. coli-strain using identical protocols as a control substance (25, 30, 31) . Non-targeted tTF has never shown visible antitumor effects or thrombogenic efficacy in vivo, and this also excludes endotoxin effects. Because of the lack of activity of tTF, within this series of experiments, we have used saline instead of tTF as control vehicle.
The investigation reported here was undertaken to test for alternative and potentially easier routes of application. Results show that s.c. injection of tTF-NGR is causing tumor growth delay of HT1080 fibrosarcoma xenografts in vivo. However, doses therapeutically active as i.v. infusions (1 mg/kg bw) (30), had only low or no effect after s.c. injection, and higher doses with antitumor activity occurred together with limiting toxicity not allowing for a safe therapeutic window. Thus, s.c. injection of tTF-NGR represents an active, but toxic application procedure and compares unfavourably to the i.v. infusion. The i.v. infusion of tTF-NGR and analogs alone or in combination with cytotoxic drugs and/or radiation will be further studied as an experimental antitumor therapy.
